BioCentury
ARTICLE | Clinical News

Genasense oblimerson: Phase II data

December 12, 2005 8:00 AM UTC

Genta Inc. (GNTA), Berkeley Heights, N.J. Business: Cancer Product: Genasense oblimerson ( G3139) Description: Antisense agent targeting Bcl-2 mRNA Molecular target: Bcl-2 mRNA Indication: Treat imat...